EE528 Analysis of Non-Pharmacological Cost Savings Derived from the Use of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients with HER2-Positive Breast Cancer in Spain
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.793
https://www.valueinhealthjournal.com/article/S1098-3015(23)03923-2/fulltext
Title :
EE528 Analysis of Non-Pharmacological Cost Savings Derived from the Use of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients with HER2-Positive Breast Cancer in Spain
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03923-2&doi=10.1016/j.jval.2023.09.793
First page :
Section Title :
Open access? :
No
Section Order :
10280